Myocardial Infarction Occurs with a Similar 24 h Pattern in the 4G/5G Versions of Plasminogen Activator Inhibitor-1

References

• Andreasen P A, Nielsen L S, Kristensen P, Grondahl-Hansen J, Skriver L, Dano K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem. 1986; 261: 7644–7651
   PubMedGoogle Scholar
• Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol. Int. 1991; 8: 336–351
   PubMed Web of Science ®Google Scholar
• Angleton P, Chandler W L, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101–106
   PubMed Web of Science ®Google Scholar
• Antman E M, Anbe D T, Armstrong P W, Bates E R, Green L A, Hand M, Hochman J S, Krumholz H M, Kushner F G, Lamas G A, Mullany C J, Ornato J P, Pearle D L, Sloan M A, Smith S C, Jr, Alpert J S, Anderson J L, Faxon D P, Fuster V, Gibbons R J, Gregoratos G, Halperin J L, Hiratzka L F, Hunt S A, Jacobs A K. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110: e82–e292
   PubMed Web of Science ®Google Scholar
• Berry C N, Lunven C, Lechaire I, Girardot C, O'Connor S E. Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis. Br. J. Pharmacol. 1998; 125: 29–34
   PubMedGoogle Scholar
• Biemond B J, Levi M, Coronel R, Janse M J, ten Cate J W, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 1995; 91: 1175–1181
   PubMed Web of Science ®Google Scholar
• Booth N A, MacGregor I R, Hunter N R, Bennett B. Plasminogen activator inhibitor from human endothelial cells. Purification and partial characterization. Eur. J. Biochem. 1987; 165: 595–600
   PubMedGoogle Scholar
• Booth N A, Robbie L A, Croll A M, Bennett B. Lysis of platelet-rich thrombi: the role of PAI-1. Ann. NY Acad. Sci. 1992; 667: 70–80
   PubMed Web of Science ®Google Scholar
• Cannon C P, McCabe C H, Stone P H, Schactman M, Thompson B, Theroux P, Gibson R S, Feldman T, Kleiman N S, Tofler G H, Muller J E, Chaitman B R, Braunwald E. Circadian variation in the onset of unstable angina and non-Q-wave acute myocardial infarction (the TIMI III Registry and TIMI IIIB). Am. J. Cardiol. 1997; 79: 253–258
   PubMed Web of Science ®Google Scholar
• Christian T F, Milavetz J J, Miller T D, Clements I P, Holmes D R, Gibbons R J. Prevalence of spontaneous reperfusion and associated myocardial salvage in patients with acute myocardial infarction. Am. Heart J. 1998; 135: 421–427
   PubMed Web of Science ®Google Scholar
• Cohen M C, Rohtla K M, Lavery C E, Muller J E, Mittleman M A. Meta-analysis of the morning excess of acute myocardial infarction and sudden cardiac death. Am. J. Cardiol. 1997; 79: 1512–1516
   PubMed Web of Science ®Google Scholar
• Coleman P L, Barouski P A, Gelehrter T D. The dexamethasone-induced inhibitor of fibrinolytic activity in hepatoma cells. A cellular product which specifically inhibits plasminogen activation. J. Biol. Chem. 1982; 257: 4260–4264
   PubMedGoogle Scholar
• Davey S G, Ebrahim S. “Mendelian randomization”: Can genetic epidemiology contribute to understanding environmental determinants of disease?. Int. J. Epidemiol. 2003; 32: 1–22
   PubMed Web of Science ®Google Scholar
• Davey S G, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures?. BMJ 2005; 330: 1076–1079
   PubMedGoogle Scholar
• Dawson S J, Wiman B, Hamsten A, Green F, Humphries S, Henney A M. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J. Biol. Chem. 1993; 268: 10739–10745
   PubMed Web of Science ®Google Scholar
• Engel H J, Lichtlen P. [Indications for a spontaneous thrombolysis in the human coronary system—coronary stenosis as a dynamic process?]. Verh. Dtsch. Ges. Inn. Med. 1977; 83: 245–249 [in German]
   PubMedGoogle Scholar
• Gils A, Declerck P J. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb. Haemost 2004; 91: 425–437
   PubMed Web of Science ®Google Scholar
• Haus E. Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention. Adv. Drug. Deliv. Rev. 2007; 59: 966–984
   PubMed Web of Science ®Google Scholar
• Hermans P W, Hibberd M L, Booy R, Daramola O, Hazelzet J A, de Groot R, Levin M. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet. 1999; 354: 556–560
   PubMed Web of Science ®Google Scholar
• Hoekstra T, Geleijnse J M, Schouten E G, Kluft C. Diurnal variation in PAI-1 activity predominantly confined to the 4G-allele of the PAI-1 gene. Thromb. Haemost. 2002; 88: 794–798
   PubMedGoogle Scholar
• Juhan-Vague I, Moerman B, De Cock F, Aillaud M F, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb. Res. 1984; 33: 523–530
   PubMed Web of Science ®Google Scholar
• Kapiotis S, Jilma B, Quehenberger P, Ruzicka K, Handler S, Speiser W. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation 1997; 96: 19–21
   PubMed Web of Science ®Google Scholar
• Keavney B. Genetic epidemiological studies of coronary heart disease. Int. J. Epidemiol. 2002; 31: 730–736
   PubMed Web of Science ®Google Scholar
• Kruithof E K, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645–1653
   PubMed Web of Science ®Google Scholar
• Lee C W, Hong M K, Lee J H, Yang H S, Kim J J, Park S W, Park S J. Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction. Am. J. Cardiol. 2001; 87: 951–954
   PubMed Web of Science ®Google Scholar
• Leiza J RG, de Llano J MA, Messa J BL, Lopez C A, Fernandez J A. New insights into the circadian rhythm of acute myocardial infarction in subgroups. Chronobiol. Int. 2007; 24: 129–141
   PubMed Web of Science ®Google Scholar
• Levi M, Biemond B J, van Zonneveld A J, ten Cate J W, Pannekoek H. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85: 305–312
   PubMed Web of Science ®Google Scholar
• Liem S S, van der Hoeven B L, Oemrawsingh P V, Bax J J, van der Bom J G, Bosch J, Viergever E P, van Rees C, Padmos I, Sedney M I, van Exel H J, Verwey H F, Atsma D E, van der Velde E T, Jukema J W, van der Wall E E, Schalij M J. MISSION!: Optimization of acute and chronic care for patients with acute myocardial infarction. Am. Heart J. 2007; 153: 14.e1–14.e11
   Google Scholar
• Maemura K, de la Monte S M, Chin M T, Layne M D, Hsieh C M, Yet S F, Perrella M A, Lee M E. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J. Biol. Chem. 2000; 275: 36847–36851
   PubMed Web of Science ®Google Scholar
• Marler J R, Price T R, Clark G L, Muller J E, Robertson T, Mohr J P, Hier D B, Wolf P A, Caplan L R, Foulkes M A. Morning increase in onset of ischemic stroke. Stroke 1989; 20: 473–476
   PubMed Web of Science ®Google Scholar
• Muller J E, Stone P H, Turi Z G, Rutherford J D, Czeisler C A, Parker C, Poole W K, Passamani E, Roberts R, Robertson T. Circadian variation in the frequency of onset of acute myocardial infarction. N. Engl. J. Med. 1985; 313: 1315–1322
   PubMed Web of Science ®Google Scholar
• Muller J E, Ludmer P L, Willich S N, Tofler G H, Aylmer G, Klangos I, Stone P H. Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75: 131–138
   PubMed Web of Science ®Google Scholar
• Nordenhem A, Leander K, Hallqvist J, de Faire U, Sten-Linder M, Wiman B. The complex between tPA and PAI-1: Risk factor for myocardial infarction as studied in the SHEEP project. Thromb. Res. 2005; 116: 223–232
   PubMedGoogle Scholar
• Oehlert G W. A note on the delta method. Am. Stat. 1992; 46: 27–29
   Web of Science ®Google Scholar
• Ohkura N, Oishi K, Sakata T, Kadota K, Kasamatsu M, Fukushima N, Kurata A, Tamai Y, Shirai H, Atsumi G, Ishida N, Matsuda J, Horie S. Circadian variations in coagulation and fibrinolytic factors among four different strains of mice. Chronobiol. Int. 2007; 24: 651–669
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Touitou Y, Smolenski M F. Ethical and methodological standards for laboratory and medical biological rhythm research. Chronobiol. Int. 2008; 25: 999–1016
   PubMed Web of Science ®Google Scholar
• Ridker P M, Vaughan P E, Stampfer M J, Manson J E, Hennehens C H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165–1168
   PubMed Web of Science ®Google Scholar
• Rupin A, Martin F, Vallez M O, Bonhomme E, Verbeuren T J. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles. Thromb. Haemost 2001; 86: 1528–1531
   PubMed Web of Science ®Google Scholar
• Sibbing D, von Beckerath O, von Beckerath N, Koch W, Mehilli J, Schwaiger M, Schomig A, Kastrati A. Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. Blood Coagul. Fibrinolysis 2005; 6: 511–515
   Google Scholar
• Smolensky M H, Hermida R C, Portaluppi F, Haus E. Twenty-four-hour pattern of angina pectoris, myocardial infarction, and sudden cardiac death: Potential role of blood pressure, heart rate and rate-pressure product circadian rhythms. Biol. Rhythm Res. 2007; 38: 205–216
   Web of Science ®Google Scholar
• Swan H J. Acute myocardial infarction: a failure of timely, spontaneous thrombolysis. J. Am. Coll. Cardiol. 1989; 13: 1435–1437
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Ardissino D, Betriu A, Cokkinos D V, Falk E, Fox K A, Julian D, Lengyel M, Neumann F J, Ruzyllo W, Thygesen C, Underwood S R, Vahanian A, Verheugt F W, Wijns W. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur. Heart J. 2003; 24: 28–66
   PubMed Web of Science ®Google Scholar
• van der Bom J G, Bots M L, Haverkate F, Kluft C, Grobbee D E. The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 2003; 101: 1841–1844
   PubMed Web of Science ®Google Scholar
• van Giezen J J, Wahlund G, Nerme T Abrahamsson. The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis. Thromb. Haemost 1997; 77: 964–969
   PubMedGoogle Scholar
• Wagner O F, Vetterlein M, Binder B R. Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line. J. Biol. Chem. 1986; 261: 14474–14481
   PubMedGoogle Scholar
• Westendorp R G, Hottenga J J, Slagboom P E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354: 561–563
   PubMed Web of Science ®Google Scholar